ORGANIZATION
New Special Rule for “Indication Change” Re-Pricing Significantly Lacks Predictability: FPMAJ
A new special rule introduced this April to expand the coverage of “indication change re-pricing” significantly lacks predictability and should be carefully applied given that it is implemented merely based on projections, the Federation of Pharmaceutical Manufacturers’ Associations of Japan…
To read the full story
Related Article
ORGANIZATION
- Labor Group Urges Priority Supply of Petrochemical Products for Drug Manufacturing
May 15, 2026
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





